Targeting Efflux Pumps to Overcome Antifungal Drug Resistance
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Resistance to antifungal drugs is an increasingly significant clinical problem. The most common antifungal resistance encountered is efflux pump-mediated resistance of Candida species to azole drugs. One approach to overcome this resistance is to inhibit the pumps and chemosensitize resistant strains to azole drugs. Drug discovery targeting fungal efflux pumps could thus result in the development of azole-enhancing combination therapy. Heterologous expression of fungal efflux pumps in Saccharomyces cerevisiae provides a versatile system for screening for pump inhibitors. Fungal efflux pumps transport a range of xenobiotics including fluorescent compounds. This enables the use of fluorescence-based detection, as well as growth inhibition assays, in screens to discover compounds targeting efflux-mediated antifungal drug resistance. A variety of medium- and high-throughput screens have been used to identify a number of chemical entities that inhibit fungal efflux pumps.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but that tolerance is not a function of either uptake or efflux rates, despite the well-known role of efflux in drug resistance [65][66][67][68][69] .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [66]
Citations
Cites
1 retracted
Maurya, I. K., Thota, C. K., Verma, S. D., Sharma, J., Rawal, M. K., Ravikumar, B., Sen, S., Chauhan, N., Lynn, A. M., Chauhan, V. S., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467159 · Cited by 33
RetractedZhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290
The Antimicrobial Resistance Crisis: Causes, Consequences, and Management
Michael, C. A., Dominey-Howes, D., & Labbate, M. (2014) · Frontiers in Public Health · doi:10.3389/fpubh.2014.00145 · Cited by 974
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Crystal structures of a multidrug transporter reveal a functionally rotating mechanism
Murakami, S., Nakashima, R., Yamashita, E., Matsumoto, T., & Yamaguchi, A. (2006) · Nature · doi:10.1038/nature05076 · Cited by 773
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Self-citationResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Research works printed but not linked: 2
- Cannon R SklarLA LindsleyC. Phenotypic HTS multiplex for anti-fungal efflux pump inhibitors. PubChem Bioassay Screening Summary; PubChem AID 485335 (2010). http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=485335.
- Hartland CL , YoungsayeW, DockendorffCet al. Identification of small molecules that selectively inhibit fluconazole-resistant Candida albicans in the presence of fluconazole but not in its absence – Probe 3. In : Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD (2010).
Cited by
Items 101–159 of 159
Saini, M., Rabbani, S. A., El-Tanani, M., Sharma, S., & Kumar, R. (2026) · Micro · doi:10.3390/micro6020036 · Cited by 4
“These efflux pumps actively export azole compounds from fungal cells, thereby reducing the concentration of azole inside fungal cells below the level needed to inhibit or kill yeast and fungi [180].”
Reversal of Azole Resistance in Candida albicans by Human Neutrophil Peptide
Khan, M. I., Choudhry, H., Jahan, S., & Rather, I. A. (2023) · Biomedicines · doi:10.3390/biomedicines11020513 · Cited by 4
“In the previous study, synthetic peptides and octapeptides have been reported to reverse the azole resistance in FLC-resistant isolates [34].”
BackgroundAonofriesei, F. (2023) · Microorganisms · doi:10.3390/microorganisms12010051 · Cited by 4
Do mitochondria use efflux pumps to protect their ribosomes from antibiotics?
Islam, M. D., Harrison, B. D., Li, J. J.-Y., Mcloughlin, A. G., & Court, D. A. (2023) · Microbiology · doi:10.1099/mic.0.001272 · Cited by 5
Anti-virulence and anti-efflux pump activity of synthetic defensins and histatin in Candida auris
Shaban, S., Patel, M., & Ahmad, A. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107644 · Cited by 3
Conn, B. N., Lieberman, J. A., Chatman, P., Cotton, K., Essandoh, M. A., Ebqa’ai, M., Nelson, T. L., & Wozniak, K. L. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1339303 · Cited by 3
Bioactive Potential of Streptomyces Spp. Against Diverse Pathogenic Fungi
Harsha, H., Kumar, M., Kumar, P., Solanki, R., & Kapur, M. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_21 · Cited by 3
Functional analysis of Candida albicans Cdr1 through homologous and heterologous expression studies
Zhao, M., Lamping, E., Niimi, K., Niimi, M., & Cannon, R. D. (2025) · FEMS Yeast Research · doi:10.1093/femsyr/foaf012 · Cited by 3
“…resistance of clinical C. albicans isolates, m uc h r esearc h has been focused on de v eloping inhibitors of Cdr1 pump function in order to overcome efflux-mediated resistance and restore fluconazole sensitivity (Schuetzer-Muehlbauer et al. 2003a , Sharma and Prasad 2011 , Holmes et al. 2016 ).”
Self-citationUtami, A. N., Tasya, A. N., Nora, R. L. D., & Wibawa, T. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002106 · Cited by 2
Prochelators modulate azole activity against Candida albicans in a metal-dependent manner
Merriman, M. A., Denning-Jannace, C. A., Hurtado, A. B., Vaccaro, F. A., Sung, Y., Tomat, E., & Franz, K. J. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00073h · Cited by 2
Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance
Arana, L., Guridi, A., Sevillano, E., Tamayo, E. H., Eraso, E., Alkorta, I., & Maté, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104487 · Cited by 2
“This mechanism severely compromises clinical outcomes and is considered a major hurdle for effective antifungal therapy [142].”
Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden
Baral, B. (2026) · ChemFoodChem · doi:10.1002/cfch.70026 · Cited by 2
Herbal formulations for the treatment of fungal infection
Patel, M., Patel, K., Bera, K., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15383-9.00030-5 · Cited by 3
Elsouk, A. S., Turki, Z. A., & Shahin, S. (2025) · Bioactivities · doi:10.47352/bioactivities.2963-654x.271 · Cited by 2
Love, S. L., McKeon, M. C., Vollmer, H., Paulson, J. C., Oshimura, N., Valentine, O. M., Ortiz, S. C., Hull, C. M., & Hoskins, A. A. (2025) · mSphere · doi:10.1128/msphere.00248-25 · Cited by 2
“To test this hypothesis, we identified two compounds reported to inhibit ATP-binding cassette and/or major facilitator superfamily drug efflux pumps, which are often implicated in drug resistance (28–34).”
Factors Affecting Drug Resistance and Virulence in Fungal Pathogen
Sharma, P., Kumari, D., Kumari, P., Kumar, A., & Pasrija, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_7 · Cited by 2
Ivanov, M., Stojković, D. S., & Sokóvić, M. (2025) · Springer eBooks · doi:10.1007/978-981-96-1305-2_7 · Cited by 2
Ferreira, J. A. G., & Stevens, D. A. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_13 · Cited by 1
Azole Antifungals Under Pressure: Therapeutic Challenges and Multifaceted Resistance Mechanisms
dos Santos, A. L. S., Ramos, L. S., de Mello, T. P., Viganor, L., Nonato, N. M. B. D. M., Pinheiro, R. E. E., & Branquinha, M. H. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673413219250826055238 · Cited by 1
Janeczko, M., & Lenarczyk, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010171 · Cited by 1
“A reduction in MIC upon the addition of the inhibitors was interpreted as evidence of efflux pump involvement in the resistance mechanism [52,53].”
The antiparasitic drug Nitazoxanide enhances the susceptibility of Candida albicans to fluconazole
Pan, J., Yao, Z., Zhang, J., Hu, P., Ye, L., Zhou, B., Shi, S., Sun, Y., & Zhou, T. (2026) · BMC Microbiology · doi:10.1186/s12866-025-04701-1 · Cited by 1
Zhang, Y., Yang, X., Wang, S., Su, J., & Zhu, Y. (2026) · Journal of Environmental Sciences · doi:10.1016/j.jes.2026.105572 · Cited by 1
Ahmed, N., & Chen, Z. (2026) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2026.107237 · Cited by 2
Application of natural products against fungal biofilm formation
Samreen, S., Jafri, H., & Ahmad, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88480-8.00017-0 · Cited by 1
Goés, L. D. O. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2019.tde-28062019-093429 · Cited by 2
The Development of Photo-activated Antimicrobial Dyes Against Opportunistic Infections
Jalab, M. (2020) · CLOK (University of Central Lancashire) · Cited by 1
Sun, W., & Jia, D. (2020) · doi:10.21203/rs.3.rs-31963/v1 · Cited by 1
“Commonly, intracellular accumulation of uconazole was greatly reduced because of the overexpression of drug transport pumps [49].”
BackgroundDoorley, L. A. (2023) · doi:10.21007/etd.cghs.2023.0620 · Cited by 1
Bracher, F. (2019) · Journal of Infectiology · doi:10.29245/2689-9981/2019/4.1150
MORADABADI, P., Tahghighi, A., Jalili‐Baleh, L., Foroumadi, A., Shams‐Ghahfarokhi, M., & Razzaghi‐Abyaneh, M. (2021) · Mediterranean Journal of Infection Microbes and Antimicrobials · doi:10.4274/mjima.galenos.2021.2021.34
“In this situation, finding and developing new alternative antifungal drugs are critical [9-11] , and researchers have attempted to look for new natural and synthetic products with favorable efficiency and high safety.”
COMPARAÇÃO DE TRÊS TÉCNICAS DE DIAGNÓSTICO DA DOENÇA DE HIRSCHSPRUNG
Lopes, C. C. C., Bertuci, J. V. F., Lopes, E. B., Lopes, L. C., Barros, V. D. S., Zanatta, L., dos Santos, D. L., da Costa, M. M., Dias, T. G., Adami, E. R., et al. (2021) · doi:10.22533/at.ed.77221091111
COMPARISON BETWEEN TOPICAL CLOTRIMAZOLE AND POVIDONE IODINE IN TREATMENT OF OTOMYCOSIS
Abd Alhaleem, S. A. A., Abd Al-Fattah Ibrahim, M., & Mohammad Dawood, Y. (2022) · Al-Azhar Medical Journal · doi:10.21608/amj.2022.212886
“Otomycosis commonly accompanied with bacterial coinfection, especially in cases with chronic otitis media (Holmes et al, 2016).”
BackgroundAlves, P. P., Santana, I. B., Júnior, N. D. L. G., Amado, J. R. R., da Silva, F. M. A., Nunomura, R. D. C. S., Cortez, A. C. A., de Souza, J. V. B., & de Souza, T. P. (2024) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv16n6-154
NEW STRATEGIES IN COMBATING FUNGAL PATHOGENS
Hrynzovska, A., & Bobyr, V. V. (2024) · Medical Science of Ukraine (MSU) · doi:10.32345/2664-4738.2.2024.14
Potential targets for the development of antifungal drugs
Nadeem, A. Y., Shehzad, A., Shahzad, R., Aljafary, M. A., & Al-Suhaimi, E. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18866-4.00013-4
Khoury, P. E., Zeidan, A., & Khalaf, R. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320484
“Studies are exploring the potential of using fungal pump inhibitors as an azole-enhancing combination therapy [63].”
ANTIFUNGAL THERAPY AND PESTICIDES: IS THERE A CONNECTION?
Hrynzovska, A., Bobyr, V. V., Shyrobokov, V., Vovk, I. M., Poniatovskyi, V., & Nazarchuk, O. A. (2025) · Clinical and Preventive Medicine · doi:10.31612/2616-4868.2.2025.17
Drilling down on treatment-resistant fungi with molecular machines
Santos, A. L., Tour, J. M., & Beckham, J. L. (2023) · The Conversation · doi:10.64628/aai.5au43tcpm
Medicinal Plant-Derived Nanoparticles Against Pathogenic Candida species
Kadir, A. K. M. S., Zerin, F. F., Tripura, S., Dutta, T., Malek, A., Rasool, A., & Batool, S. (2025) · Springer eBooks · doi:10.1007/978-3-032-03604-9_10 · Cited by 1
Chattaraj, B., Nigar, T., Das, A., & Nandi, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33702-4.00013-x
Yu, H., Sun, X., Zhang, K., Jiang, M., Chen, C., Lu, B., Zhang, Y., & Gao, J. (2025) · Plant Disease · doi:10.1094/pdis-08-25-1682-re
Gil, F., Laiolo, J., Bayona-Pacheco, B. L., Cannon, R. D., Ferreira‐Pereira, A., & Carpinella, M. C. (2022) · Figshare · doi:10.6084/m9.figshare.21321440
Self-citationInvestigating several putative mitochondrial pumps in Saccharomyces cerevisiae
Islam, M. D. (2021) · Mspace (University of Manitoba) · Cited by 1
Searching for efflux pumps in the mitochondria of Saccharomyces cerevisiae by proteomics
Ahmadi, N. (2025) · Mspace (University of Manitoba)
Functional characterization of Candida auris DHA1 transporters conferring flucytosine resistance
Malik, S., Saini, A., Khatoon, R., & Banerjee, A. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1806653
“These contrasting observations further strengthen the argument that CLO’s synergistic effects are primarily attributable to efflux inhibition, as echinocandins and polyenes are not part of the efflux arsenal of fungal drug transporters (Cannon et al., 2009; Holmes et al., 2016).”
Parveen, A., Karak, P., Adhikari, A., & Das, S. K. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1829493
“…requires prolonged therapy, and treatment is frequently constrained by toxicity, drug–drug interactions, and incomplete eradication in structurally abnormal niches, which can necessitate combined medical and surgical approaches in carefully selected patients (Holmes et al., 2016; Otu et al., 2023).”
Pimenta, G. R., Gualque, M. W. D. L., Siqueto, M. J., Silva, S. D. M., Regasini, L. O., Mendes‐Giannini, M. J. S., & Fusco‐Almeida, A. M. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00203-26
“FK506 reduces and inhibits these pumps (58, 67); similar effects occur with protocatechuic acid derivatives (66).”
Tankiewicz, M., Niciejewski, K., Dydecka, A., & Topka, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146247
“These transporters actively remove antifungal agents from fungal cells, reducing intracellular drug accumulation and enabling survival under fungicide exposure [52–54].”
InfluentialInsects-Derived Antifungal Peptides and Compounds: A Review of Their Potential and Mechanisms
Roy, S., Chakraborty, S., Rakhshit, S., Saha, S., Mallick, S., Majumdar, S., & Nayak, A. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101757
Choi, S., Kim, G., Son, D., Choi, J.-H., Park, S., Choi, H.-W., & Sang, H. (2026) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2026.107304
Li, S. (2026) · International Journal of Biology and Life Sciences · doi:10.54097/dq5nqv64
“According to the above synergy mechanism of increased permeability and intracellular accumulation, further tests are needed to confirm it through efflux assays, fluorescent uptake experiments and molecular-level analyses [73-74].”
Ibrahim, A. A., Khan, T., Khan, A., Obare, S. O., Dellinger, A. L., & LaJeunesse, D. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.6c01063
Rezk, A., Said, H. S., Elfeky, S. M., El‐Mowafy, M., & Hassan, R. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-13977-w
“Several inhibitors have been reported, including macrocyclics, cyclopeptides, peptidomi-metics, phenol derivatives, terpene derivatives, and disulfi-ram (Holmes et al. 2016).”
Formulation-Driven Innovation in Antifungal Therapy: From Nanotechnology to AI-Assisted Design
Rabin, D. C., Mamani, M., Baral, K. C., Kim, G. L., Jo, S.-Y., & Han, H. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s636678
“18 Polyene resistance, although less prevalent, arises from the ability of fungi to remodel their membrane composition.”
Efflux pump inhibition disrupts biofilms and enhances azole susceptibility in Candidozyma auris
Castro, K. E., Silva, M. L., Lopes, F. E. S., de Andrade, A. R. C., CARNEIRO, B. S., da Silva, L., Neto, J. M. D. M., Sidrim, J. J. C., Maia, D. C. B. D. S. C., Guedes, G. M. D. M., et al. (2026) · Biofouling · doi:10.1080/08927014.2026.2734116
“Consistent with previous in vitro (Aguiar et al. 2023; Cordeiro et al. 2020; Holmes et al. 2016) and ex vivo (Holmes et al. 2016) 3 Figure 5.”
do Nascimento, M. O., Dias, L. D. S., Meneses, A. K. S., de Lima, S. G., de Moura, C. V. R., Gutierrez, S. J. C., Barreto, H. M., do Nascimento, D. A., Zazeri, G., & Carvalho, A. L. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101229
“The discovery of new inhibitors may therefore lead to the development of combination therapies that enhance the efficacy of azoles [10–12].”
Zainul, R., Khaleq, M. A. A., Farah, H., Panigrahi, R., Muniyandy, E., Kumar, N., Mehla, S., Jead, O. Z., Dilafruz, K., & Abdullaev, A. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108854
Ye, S., Cui, Z., Zhou, M., Hu, C., Yu, P., Zhang, L., Li, S., & Sun, X. (2026) · mBio · doi:10.1128/mbio.02021-26
“The current understanding of antifungal resistance has been dominated by two major paradigms: drug target alteration and efflux pump-mediated resistance (65–68).”
Metadata
- Authors
- Holmes, A. R., Cardno, T. S., Strouse, J. J., Ivnitski-Steele, I., Keniya, M. V., Lackovic, K., Monk, B. C., Sklar, L. A., & Cannon, R. D.
- Affiliations
- University of Otago (NZ)
- The University of Melbourne (AU)
- University of New Mexico (US)
- New Mexico Center for Molecular Discovery, University of New Mexico, Albuquerque, New Mexico, USA
- Corresponding author
- Cannon, Richard D
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2016-07-27
- Volume
- 8
- Issue
- 12
- Pages
- 1485-1501
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- PMC
- PMC5827819
- OpenAlex
- W2478702959
- Cited by
- 156
- References
- 102
- Citations by year
- 2026: 20 · 2025: 24 · 2024: 18 · 2023: 24 · 2022: 16 · 2021: 14 · 2020: 18 · 2019: 10 · 2018: 6 · 2017: 6
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Medicinal Chemistry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01-DE016855-01; R03-MH087406-1A1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- antifungal resistance, efflux pumps, Candida, chemosensitization, combination therapy, heterologous expression in Saccharomyces cerevisiae, fluorescence-based screening, high-throughput screening, drug discovery
- MeSH terms
- Antifungal Agents, Azoles, Fungi, Humans, Microbial Sensitivity Tests, Mycoses, Drug Resistance, Fungal, Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.